Evidence map›Paper›PMID 35451699›Full record

ArticleJournal of cancer research and clinical oncology2023

Impact of metabolic indices of

Astrid Bauschke, Annelore Altendorf-Hofmann, Lukas Brückner, Robert Drescher, Martin Freesmeyer, Utz Settmacher

Open access · hybridFull text read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Astrid BauschkeDepartment of General, Visceral and Vascular Surgery, University Hospital Jena, Am Klinikum 1, Erlanger Allee 101, 07740, Jena, Germany. astrid.bauschke@med.uni-jena.de.ORCID http://orcid.org/0000-0002-9941-5323
Annelore Altendorf-HofmannDepartment of General, Visceral and Vascular Surgery, University Hospital Jena, Am Klinikum 1, Erlanger Allee 101, 07740, Jena, Germany.
Lukas BrücknerDepartment of General, Visceral and Vascular Surgery, University Hospital Jena, Am Klinikum 1, Erlanger Allee 101, 07740, Jena, Germany.
Robert DrescherDepartment of Nuclear Medizine, University Hospital Jena, Am Klinikum1, 07740, Jena, Germany.
Martin FreesmeyerDepartment of Nuclear Medizine, University Hospital Jena, Am Klinikum1, 07740, Jena, Germany.
Utz SettmacherDepartment of General, Visceral and Vascular Surgery, University Hospital Jena, Am Klinikum 1, Erlanger Allee 101, 07740, Jena, Germany.
Jena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor recurrence is the leading cause of death after liver transplantation in patients with hepatocellular carcinoma. There is an ongoing debate as to whether metabolic indices such as tumor to liver standardized uptake value ratio in

methodsThis retrospective study analyzes 103 consecutive patients who underwent

resultsTumor to liver standardized uptake value ratio of the primary tumor was statistically significant higher in Milan out tumors, "up-to-seven" out tumors, grade 3 tumors, α- fetoprotein level >400 ng/ml and lesions > 5cm in diameter. Factors with statistically significant influence on the 10- year overall survival in the univariate analysis were Milan, up-to-seven" criteria, number of lesions and pT-category. COX regression analysis did not show independently statistically significant factors for 10-year overall survival. Milan, "up-to-seven" criteria, grade, pV, number of lesions, size of lesion, pT-category, tumor to liver standardized uptake value ratio influenced 10-year cumulative recurrence rates statistically significant. Tumor to liver standardized uptake value ratio, grade and pT-category proved to be independently statistically significant factors for 10-year cumulative recurrence rates.

conclusionsOur study suggests that tumor to liver standardized uptake value standardized uptake value ratio in

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsFluorodeoxyglucose F18HumansNeoplasm Recurrence, LocalPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective Studiesalpha-FetoproteinsFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTHCCLiver transplantationLong-term survival

Identifiers

PMID35451699
PMCPMC10020288
OpenAlexW4225660082

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read46
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.